Publication | Closed Access
Long-term follow-up of a randomized prospective trial comparing a standard 81mg dose of intravesical bacille calmette-guérin with a reduced dose of 27mg in superficial bladder cancer.
53
Citations
0
References
2003
Year
Urological ResearchSurgical OncologyUrologyGenitourinary CancerSuperficial Bladder CancerMedicineStandard 81MgRandomized Prospective TrialPharmacotherapyOncologyRadiation OncologyCancer Research
No additional data available for this publication yet. Check back later!